Biofrontera Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“December 31, 2025, Biofrontera Inc., a Delaware corporation (the “Company”), received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that the listing of its common stock was not in compliance with Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market, as the closing bid price of the Company’s common stock was less than $1.00 per share for the previous 34 consecutive business days. The notice has no present impact on the listing or trading of the Company’s securities on The Nasdaq Capital Market. Un”
M&A Transactions
Biofrontera Inc. completed a disposition involving Pelthos Therapeutics Inc. for maximum of $10,000,000 (closed 2025-11-06).
“Capitalized terms used below that are not defined herein shall have the meanings ascribed to such terms in the APA. The purchase price for the Acquired Assets is a maximum of $10,000,000, payable as follows: 1) $3,000,000 in cash, paid on the Closing Date; 2) Subject to availability of certain commercial quantities of the Product and other terms and conditions of”
Earnings Releases
Biofrontera Inc. reported the three months ended March 31, 2024 results: revenue $7.9 million, net income $10.4 million, or $(2.88) per share, EPS $(2.88) per share.
“2024 and provided a business update. Highlights from the first quarter of 2024 and subsequent weeks included the following: ● Total revenues for the first quarter of 2024 were $7.9 million, a 9% decrease from the same period of the prior year primarily driven by reimbursement headwinds our customers experienced due to the Change Healthcare data breach ● Cash and”
Governance Changes
Biofrontera Inc.: Increased authorized shares of common stock from 15,000,000 to 35,000,000 (effective 2024-04-25).
“On April 25, 2024, Biofrontera Inc. (the “Company”) filed a Certificate of Second Amendment to its Amended and Restated Certificate of Incorporation (the “Amendment”) with the Secretary of State of the State of Delaware to increase the number of the Company’s authorized shares of common stock, par value $0.001, from 15,000,000 to 35,000,000.”
Earnings Releases
Biofrontera Inc. reported the fourth quarter of 2023 results: revenue $10.6 million, net income $3.5 million, EPS $1.65 per share.
“Total revenues for the fourth quarter of 2023 were $10.6 million, an increase of $0.5 million, or ~4%, compared with $10.1 million for the fourth quarter of 2022.”
Earnings Releases
Biofrontera Inc. reported financial results for the three and twelve months ended December 31, 2023.
“On March 15, 2024, Biofrontera Inc. (the “Company”) issued a press release announcing its financial and operational results for the fourth quarter and fiscal year ended December 31, 2023.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.